Kim Paul Y, Nesheim Michael E
Departments of Biochemistry and Medicine, Queen's University, Kingston, Ontario, Canada.
J Biol Chem. 2007 Nov 9;282(45):32568-81. doi: 10.1074/jbc.M701781200. Epub 2007 Aug 28.
Previous work showed that prothrombin derivatives cleavable only at Arg-320 (rMZ) or Arg-271 (rP2) are partial, rather than competitive, inhibitors of prothrombin activation by prothrombinase. A "ping-pong"-like model, which posits two equilibrating forms of prothrombinase, explained the inhibition pattern. The present studies were undertaken to further investigate this putative mechanism. Two models were developed, one allowing for one form of the enzyme and the other allowing for two forms. Both models also allowed channeling and ratcheting. The models were fit to full time courses of prothrombin, meizothrombin, prethrombin-2, and the B-chain. In the absence of ratcheting and channeling, neither model fits the data. In their presence, however, both models fit very well, and thus they could not be distinguished. Therefore, inhibition of rMZ activation by rP2 was studied. Inhibition was partial and the two-form model fit the data with randomly distributed residuals, whereas the one-form model did not. Initial rates of fluorescein-labeled prothrombin cleavage in the presence of various prothrombin derivatives reported by Brufatto and Nesheim (Brufatto, N., and Nesheim, M. E. (2003) J. Biol. Chem. 278, 6755-6764) were also analyzed using the two models. The two-form model fit the partial inhibition data well, whereas the one-form model did not. In addition, prothrombin at varying concentrations was activated, and subsequently, the initial rates were plotted with respect to the initial prothrombin concentration. When compared with the expected initial rates as determined by the simulation of the models, the two-form model fit the observed rates better than the one-form model. The results obtained here further support the existence of two functional forms of prothrombinase.
先前的研究表明,仅在精氨酸-320(rMZ)或精氨酸-271(rP2)处可裂解的凝血酶原衍生物是凝血酶原酶激活凝血酶原的部分抑制剂,而非竞争性抑制剂。一种类似“乒乓”的模型假定凝血酶原酶有两种平衡形式,解释了这种抑制模式。本研究旨在进一步探究这一假定机制。构建了两个模型,一个假定酶只有一种形式,另一个假定有两种形式。两个模型均考虑了通道化和棘轮效应。将模型与凝血酶原、中凝血酶、凝血酶原-2和B链的完整时间进程数据进行拟合。在没有棘轮效应和通道化的情况下,两个模型均无法拟合数据。然而,在存在棘轮效应和通道化的情况下,两个模型拟合得都很好,因此无法区分它们。因此,研究了rP2对rMZ激活的抑制作用。抑制是部分性的,双形式模型能很好地拟合数据且残差随机分布,而单形式模型则不能。Brufatto和Nesheim(Brufatto,N.,和Nesheim,M. E.(2003)J. Biol. Chem. 278,6755 - 6764)报道的在各种凝血酶原衍生物存在下荧光素标记的凝血酶原裂解的初始速率,也使用这两个模型进行了分析。双形式模型能很好地拟合部分抑制数据,而单形式模型则不能。此外,对不同浓度的凝血酶原进行激活,随后绘制初始速率相对于初始凝血酶原浓度的曲线。与通过模型模拟确定的预期初始速率相比,双形式模型比单形式模型能更好地拟合观察到的速率。此处获得的结果进一步支持了凝血酶原酶存在两种功能形式。